HER2 ADCs: Safety and Tolerability

CME

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 19, 2025

Expiration: May 18, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following statements best describes the clinical significance of interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd)?